Infliximab leaflet

Infliximab Therapeutic Drug Monitoring

Serum Infliximab and Total Anti-Infliximab Antibodies


Infliximab (Remicade®), is a chemeric human-mouse monoclonal antibody directed against tumour necrosis factor-alpha (TNF ), approved for use in the treatment of various chronic inflammatory diseases including rheumatoid arthritis, severe crohn's disease and ankylosing spondylitis. We measure serum infliximab using an in-house ELISA method.

Download Information Leaflet here...




 Infliximab Therapeutic Drug Monitoring


Clinical Biochemistry

Specimen Type:

0.5 mL Serum


-20°C prior to dispatch

Posting Details:

Ambient temperature, first class post

Posting Address:

Department of Clinical Biochemistry, City Hospital, Dudley Road, Birmingham B18 7QH

Clinical Use:

Effective use of Infliximab in clinical practice. To assess reasons for a lack of clinical response.


Serum Infliximab: 30
Anti-Infliximab antibodies: 37


Serum Infliximab Assay- within  3 working days

Anti-Infliximab Antibodies Assay - within 7 working days

External QA Scheme:

Not Applicable

CPA Accredited Lab/Test:

Yes, CPA Full Accreditation

Key Contacts:

Tel: 0121 507 3441









  SWBH NHS Trust 2018